To date, several GLP-1 RA have been tested in CV outcome trials (CVOTs) in patients with T2DM and high CV risk, with liraglutide, semaglutide, dulaglutide, albiglutide, and efpeglenatide being superior to placebo in reducing the incidence of MACE, while lixisenatide and exenatide did not achieve superiority.12 Our results show a gradual increase in the prescription of GLP-1 RA, from 5% in 2017 up to 16% in 2021. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.